Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-16T18:59:24.177Z Has data issue: false hasContentIssue false
  • English
  • Français

Growth Factors and Lymphokines: Modulators of Cholinergic Neuronal Activity

Published online by Cambridge University Press:  18 September 2015

Rémi Quirion ,
Dalia M. Araujo ,
Paul A. Lapchak ,
David Seto  and
Jean-Guy Chabot
Rémi Quirion*
Affiliation:
Departments of Psychiatry, and Pharmacology and Therapeutics, Faculty of Medicine, McGill University and Douglas Hospital Research Centre, Verdun, Quebec
Dalia M. Araujo
Affiliation:
Departments of Psychiatry, and Pharmacology and Therapeutics, Faculty of Medicine, McGill University and Douglas Hospital Research Centre, Verdun, Quebec
Paul A. Lapchak
Affiliation:
Departments of Psychiatry, and Pharmacology and Therapeutics, Faculty of Medicine, McGill University and Douglas Hospital Research Centre, Verdun, Quebec
David Seto
Affiliation:
Departments of Psychiatry, and Pharmacology and Therapeutics, Faculty of Medicine, McGill University and Douglas Hospital Research Centre, Verdun, Quebec
Jean-Guy Chabot
Affiliation:
Departments of Psychiatry, and Pharmacology and Therapeutics, Faculty of Medicine, McGill University and Douglas Hospital Research Centre, Verdun, Quebec
*
Douglas Hospital Research Centre, 6875 Blvd. LaSalle, Verdun, Quebec, Canada H4H 1R3
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

It is well known that various markers of the cholinergic synapse are altered in Alzheimer's Disease. Much interest is currently focussing on the evaluation of the possible efficacy of certain growth factors, especially nerve growth factor (NGF), to reduce or reverse cholinergic neuronal losses. Here we report that other growth factors (epidermal growth factor and insulin-like growth factor I) and a lymphokine, interleukin-2, are able to block acetylcholine release in the rat hippocampus. This suggests that while certain growth factors like NGF may have positive effects on the cholinergic neuron, others may act as “negative” factors on this neuronal population.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue S3 , August 1991 , pp. 390 - 393
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

REFERENCES

1.Gottfries, CG. Neurochemical aspects of dementia disorders. Dementia 1990; 1: 54.64.Google Scholar
2.Quirion, R, Aubert, I, Robitaille, Y, et al. Neurochemical deficits in pathological brain ageing. Specificity and possible relevance for treatment strategies. Clin Neuropharmacol 1990; 13: 573–580.CrossRefGoogle ScholarPubMed
3.Quirion, R. Déficits neurochimiques observes dans la maladie d’Alzheimer. Médecine Sciences 1990; Supp. 2, 4A-8A.Google Scholar
4.Mash, DC, Flynn, DD and Potter, LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science 1985; 228: 1115–1117.CrossRefGoogle ScholarPubMed
5.Araujo, DM, Lapchak, PA, Robitaille, Y, et al. Differential alteration of various cholinergic markers in cortical and subcortical regions of the human brain in Alzheimer’s disease. J Neurochem 1988; 50: 1914–1923.CrossRefGoogle ScholarPubMed
6.Quirion, R, Aubert, L, Lapchak, PA, et al. Muscarinic receptor subtypes in human neurodegenerative diseases: focus on Alzheimer’s Disease. Trends Pharmacol Sci Suppl 1989; 4: 80–84.Google Scholar
7.Hadhazy, P and Szerb, JC. The effect of cholinergic drugs on [3H] acetylcholine release from slices of rat hippocampus, striatum and cortex. Brain Res 1977; 123: 311–322.CrossRefGoogle ScholarPubMed
8.Szerb, JC, Hadhazy, P and Dudar, JD. Release of [3H] acetylcholine from rat hippocampal slices: effect of septal lesion and graded concentrations of muscarinic agonists and antagonists. Brain Res 1977; 128: 285–291.CrossRefGoogle ScholarPubMed
9.Raiteri, M, Leardi, R and Marchi, M. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain J Pharmacol Exp Ther 21984; 228: 209–214.Google ScholarPubMed
10.Marchi, M and Raiteri, M. On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties. J Pharmacol Exp Ther 1985; 235: 230–233.Google ScholarPubMed
11.Poborecki, R, Head, R and Domino, EF. Effects of selected muscarinic cholinergic antagonists of [3H] acetylcholine release from rat hippocampal slices. J Pharmacol Exp Ther 1988; 244: 213–217.Google Scholar
12.Lapchak, PA, Araujo, DM, Quirion, R, et al. Binding sites for [3H] AF-DX116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Res 1989; 496: 285–294.CrossRefGoogle Scholar
13.Fisher, A, Gurwitz, D, Haring, H, et al. Physiological actions of an M, muscarinic agonist, AF102B. Soc Neurosci Abstr 1990; 16: 203.Google Scholar
14.Hefti, F, Hartikka, J and Knusel, B. Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiol Aging 1989; 10: 515–533.CrossRefGoogle ScholarPubMed
15.Perry, E. Nerve growth factors and the basal forebrain cholinergic systems: a link in the etiopathology of neurodegenerative dementias. Alz Dis Assoc Disord 1990; 4: 1–13.CrossRefGoogle ScholarPubMed
16.Araujo, DM, Chabot, JG and Quirion, R. Potential neurotrophic factors in the mammalian central nervous system: functional significance in the developing and aging brain. Int Rev Neurobiol 1990; 32: 141–174.CrossRefGoogle ScholarPubMed
17.Haroutunian, V, Kanof, PD and Davis, KL. Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res 1986; 386: 397–399.CrossRefGoogle ScholarPubMed
18.Fischer, W, Wictorin, K, Bjorklund, A, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987; 329: 65–68.CrossRefGoogle ScholarPubMed
19.Goedert, M, Fine, A, Dawbarn, D, et al. Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal fore-brain in Alzheimer’s disease. Mol Brain Res 1989; 5: 1–7.CrossRefGoogle Scholar
20.Kordower, JH and Mufson, EJ. NGF and Alzheimer’s disease: unfulfilled promise and untapped potential. Neurobiol Aging 1989; 10: 543–544.CrossRefGoogle ScholarPubMed
21.Dugich-Djordjevic, M, Burton, LE, Bennett, GL, et al. Recombinant human NGF labels a novel high affinity binding site in rat brain. Soc Neurosci Abstr 1990; 16: 825.Google Scholar
22.Yankner, BA, Caceres, A and Duffy, LK. Nerve growth factor potentiates the neurotoxicity of ?-amyloid. Proc Natl Acad Sci USA 1990; 87: 9020–9123.CrossRefGoogle ScholarPubMed
23.Ishii, DN and Recio-Pinto, E. Role of insulin, insulinlike growth factors and nerve growth factor in neurite formation. In: Insulin, insulin-like growth factors, and their receptors in the central nervous system. Raizada, MKPhillips, MI and LeRoith, D eds.: New York and London: Plenum Press 1987; 315–348.CrossRefGoogle Scholar
24.Marx, J. NGF and Alzheimer’s: Hopes and fears. Science 1990; 247: 408–410.CrossRefGoogle ScholarPubMed
25.Quirion, R, Araujo, D, Nair, NVP, et al. Visualization of growth factor receptor sites in rat forebrain. Synapse 1988; 2: 212–218.CrossRefGoogle ScholarPubMed
26.Araujo, DM, Lapchak, PA, Collier, B, et al. Insulin-like growth factor- 1 (somatomedin-C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system. Brain Res 1989; 484: 130–138.CrossRefGoogle ScholarPubMed
27.Araujo, DM, Lapchak, PA, Chabot, J.-G., et al. Growth factor and lymphokine effects on brain cholinergic system., In: Mayer, EM, Simpkins, JW and Yamamoto, J. eds. Novel Approaches to the Treatment of Alzheimer’s Disease. Plenum Pubi Corp 1989; 153–163.CrossRefGoogle Scholar
28.Araujo, DM, Lapchak, PA, Collier, B and Quirion, R.Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system. Brain Res 1989; 498: 257–266.CrossRefGoogle ScholarPubMed
29.Lapchak, PA, Araujo, DM, Quirion, , et al. Immunoautoradiographic localization of interleukin-2 and interleukin-2 receptor (Tac antigen) in the rat brain. Neuroscience, in press.Google Scholar
30.Baskin, DG, Wilcox, BJ, Figlewicz, DP, et al. Insulin and insulin-like growth factors in the CNS. Trends Neurosci 1988; 11: 107–111.CrossRefGoogle ScholarPubMed
31.Bohannon, NJ, Corp, ES, Wilcox, BJ, et al. Localization of binding sites for insulin-like growth factor I (IGF-I) in the rat brain by quantitative autoradiography. Brain Res 444: 205–213.CrossRefGoogle Scholar
32.Seto, D, Diorio, D, Rowe, , et al. Effects of age and cognitive status on rat brain insulin-like growth factor-I binding site levels. Soc Neurosci Abstr 1990; 16: 842.Google Scholar
33.Adem, A, Jossan, SS, D’Argy, R, et al. Insulin-like growth factor 1 IGF-1) receptors in the human brain: Quantitative autoradiographic localization. Brain Res 1989; 503: 299–303.CrossRefGoogle ScholarPubMed
34.Yamaguchi, F, Itano, T, Miyamoto, O, et al. Increase in extracellular insulin-like growth factor I (IGF-I) concentration following elec-trolytical lesion in rat hippocampus. Neurosci Lett, in press.Google Scholar
35.Hansson, HA, Dahlin, LB, Danielsen, N, et al. Evidence indicating trophic importance of IGF-I in regenerating peripheral nerves. Acta Physiol Scand 1986; 126: 609–614.CrossRefGoogle ScholarPubMed
36.Nieto-Sampedro, M, Lewis, ER, Cotman, CW, et al. Brain injury causes a time-dependent increase in neurotrophic activity at the lesion site. Science 1982; 217: 860–861.CrossRefGoogle Scholar
37.Nieto-Sampedro, M, Saneto, RP, de Vellis, J, et al. The control of glial populations in brain: Changes in astrocyte mitogenic and morphogenic factors in response to injury. Brain Res 1985; 343: 320–328.CrossRefGoogle ScholarPubMed
38.Gomez-Pinilla, F, Knauer, DJ, Nieto-Sampedro, M. Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization. Brain Res 1988; 238: 72–75.Google Scholar
39.Morrison, RS, Kornblum, HI, Leslie, FM, et al. Trophic stimulation of cultured neurons from neonatal rat brain by epidermal growth factor. Science 198; 238: 72–75.CrossRefGoogle Scholar
40.McGeer, PL, Akiyama, H, Itagaki, S, et al. Immune system response in Alzheimer’s Disease. Can J Neurol Sci 1989; 16 Suppl: 516–527.CrossRefGoogle ScholarPubMed
41.Nieto-Sampedro, M, Chandy, KG. Interleukin-2 -like activity in injured rat brain. Neurochem Res 1987; 12: 723–727.CrossRefGoogle ScholarPubMed
42.Beaudet, A, Araujo, DM, Quirion, R, et al. Immunoautoradiographic localization of interleukin-2 receptor (Tac antigen) in rat and human brain. Soc Neurosci Abstr 1990; 18: 12–13.Google Scholar
43.Araujo, DM, Lapchak, PA, Collier, B, et al. Interleukin-2 interacts with opioid neuroregulatory systems in the rat hippocampus. In: Quirion, R, Jhamandas, K and Gianoulakis, C. eds. INRC-89. Prog Clin Biol Res 1990; vol 328. New York: Alan R Liss 1990: 355–358.Google Scholar
44.Tancredi, V, Zona, C, Velotti, F, et al. Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. Brain Res 1990; 525: 149–151.CrossRefGoogle ScholarPubMed
45.Itagaki, S, McGeer, PL, Tago, H, et al. Expression of HLA-DR and interleukin-2 receptor on reactive microglia in senile dementia of the Alzheimer type. Soc Neurosci Abstr 1987; 13: 366.15.Google Scholar